Tüdőrák: vizsgálatok itt: Románia

In Románia 55 Also abroad 2733

55 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.

3. fázisTaking people
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
Where
Cluj-Napoca, Craiova, Timisoara
Életkor
18 év and over
People
340 worldwide
Run by
OSE Immunotherapeutics
See details and how to join2023-509340-10-00 · EU 2023-509340-10-00
3. fázisTaking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Bucharest, Cluj-Napoca, Craiova, Iași, Otopeni, Ploieşti
Életkor
18 év and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
2/3. fázisTaking people
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where
Bucharest, Cluj-Napoca, Craiova, Floresti, Iasi, Iași, Otopeni, Ploieşti
Életkor
18 év and over
People
590 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00
3. fázisTaking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Baloteşti, Bucharest, Cluj-Napoca, Craiova, Floresti, Iasi, Iași, Timisoara
Életkor
18 év and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
2. fázisTaking people
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Bucharest, Cluj-Napoca, Craiova, Floresti, Iasi, Iași, Timișoara
Életkor
18 év and over
People
160 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680764 · EU 2026-525170-19-00
3. fázisTaking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Bucharest, Cluj-Napoca, Craiova, Iași, Ovidiu, Ploieşti, Timișoara
Életkor
18 év and over
People
695 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06801834
3. fázisTaking people
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
Where
Bucharest, Cluj-Napoca, Craiova, Galati, Iasi, Iași, Timișoara
Életkor
18 év and over
People
263 worldwide
Run by
Zai Lab (US) LLC
See details and how to join2025-522818-23-00 · EU 2025-522818-23-00
2. fázisTaking people
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
Where
Craiova, Piteşti, Sibiu, Timișoara
Életkor
18 év and over
People
107 worldwide
Run by
CatalYm GmbH
See details and how to joinNCT07098988 · EU 2024-516792-32-01
3. fázisTaking people
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Where
Baia Mare, Bucharest, Cluj-Napoca, Craiova, Iasi, Onesti, Jud. Bacau, Timisoara, Timișoara
Életkor
18 év and over
People
621 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712355 · EU 2024-515765-34-00
2/3. fázisNot yet taking people in Románia
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Where
Bucharest, Cluj-Napoca, Craiova, Floresti, Iasi, Iași
Életkor
18 év and over
People
173 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2025-521908-22-00 · EU 2025-521908-22-00
3. fázisTaking people
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Where
Bucharest, Floresti, Ovidiu, Ploiesti, Satu Mare, Timișoara
Életkor
18 év and over
People
360 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00
2. fázisNot yet taking people in Románia
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
Where
Bucharest, Cluj-Napoca, Iași
Életkor
18 év and over
People
80 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07871214
2/3. fázisTaking people
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Where
Bucharest, Cluj-Napoca, Craiova, Florești, Iași
Életkor
18 év and over
People
500 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07100080
3. fázisTaking people
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Where
Cluj-Napoca, Craiova, Timișoara
Életkor
18 év and over
People
363 worldwide
Run by
OSE Immunotherapeutics
See details and how to joinNCT06472245
2. fázisTaking people
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Where
Bucharest, Craiova
Életkor
18 év and over
People
243 worldwide
Run by
Shanghai Henlius Biotech
See details and how to joinNCT06907615 · EU 2025-523803-31-00
3. fázisTaking people
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Where
Bucharest, Cluj-Napoca, Craiova, Floresti, Iași, Ovidiu, Timisoara, Timișoara
Életkor
18 év and over
People
714 worldwide
Run by
Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00
3. fázisTaking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Where
Bucharest, Craiova, Otopeni, Pitesti, Sibiu, Timisoara
Életkor
18 év and over
People
830 worldwide
Run by
AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00
3. fázisTaking people
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Where
Baia Mare, Bucharest, Cluj-Napoca, Craiova, Floresti, Iasi, Ovidiu, Piatra Neamt, Suceagu, Timisoara, Timișoara
Életkor
18 év and over
People
780 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00
2. fázisTaking people
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Where
Bucharest, Cluj-Napoca, Craiova, Floresti, Iasi, Iași
Életkor
18 év and over
People
182 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06855771 · EU 2024-519814-29-00
1/2. fázisTaking people
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Where
Bucharest, Cluj-Napoca, Craiova
Életkor
18 év and over
People
118 worldwide
Run by
MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07407933
3. fázisTaking people
Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
Where
Bucharest, Cluj-Napoca, Iași, Timișoara
Életkor
18 év and over
People
168 worldwide
Run by
Amgen Inc.
See details and how to join2026-525489-23-00 · EU 2026-525489-23-00
1/2. fázisTaking people
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Where
Craiova, Timișoara
Életkor
18 év and over
People
240 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07325136 · EU 2025-524090-16-00
1/2. fázisTaking people
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Where
Bucharest, Cluj-Napoca
Életkor
18 év and over
People
250 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06657222 · EU 2025-522517-35-00
3. fázisTaking people
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Where
Suceava
Életkor
18 év and over
People
87 worldwide
Run by
Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00
3. fázisTaking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Bucharest, Craiova, Floresti, Iași, Ovidiu, Ploieşti, Timisoara
Életkor
18 év and over
People
355 worldwide
Run by
Gilead Sciences Inc.
See details and how to join2024-515884-69-00 · EU 2024-515884-69-00